Celsion Corp., of Lawrenceville, N.J., said the latest overall survival data from its posthoc analysis of the Phase III HEAT study of Thermodox, the firm’s heat-activated liposomal encapsulation of doxorubicin, in combination with radio frequency ablation (RFA) supported the continued clinical development in a prospective Phase III pivotal study, subject to regulatory review and agreement.